Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
This review summarizes and describes the use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease. For diagnosis of Alzheimer's disease, amyloid-β and highly phosphorylated tau protein are the major biomarkers. Curcumin was developed as an early diagnostic probe based on its natural fluorescence and high binding affinity to amyloid-β. Because of its multi-target effects, curcumin has protective and preventive effects on many chronic diseases such as cerebrovascular disease, hypertension, and hyperlipidemia. For prevention and treatment of Alzheimer's disease, curcumin has been shown to effectively maintain the normal structure and function of cerebral vessels, mitochondria, and synapses, reduce risk factors for a variety of chronic diseases, and decrease the risk of Alzheimer's disease. The effect of curcumin on Alzheimer's disease involves multiple signaling pathways: anti-amyloid and metal iron chelating properties, antioxidation and anti-inflammatory activities. Indeed, there is a scientific basis for the rational application of curcumin in prevention and treatment of Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“(Yang et al., 2005).”
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 1×
“In turn, this induces inflammatory responses and increases Aβ influx, giving rise to further brain damage and ensuing cognitive impairment (Yan et al., 1996).”
BackgroundSelf-citationAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“Clinically, AD is characterized by memory and cognitive impairments, and personality and behavior changes (Huang and Mucke, 2012).”
BackgroundEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254 · cited 2×
“In vitro curcumin displays high-affinity binding to Aβ aggregates (Kd = 0.20 nM), with EC50 of curcumin for Aβ destabilization being approximately 1 µM (Ono et al., 2004).”
BackgroundInfluentialJin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“In particular, Aβ dimers (the major form of soluble oligomers isolated from AD cortex) directly induce tau hyperphosphorylation and neurite degeneration (Jin et al., 2011).”
Backgroundβ-Amyloid Monomers Are Neuroprotective
Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1736-09.2009 · Cited by 421 · cited 1×
“This results in native Aβ monomers that have prosurvival effects on neurons and protect mature neurons against excitotoxic death (Giuffrida et al., 2009).”
BackgroundAnimal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419
Cox, K. H., Pipingas, A., & Scholey, A. B. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114552744 · Cited by 368
Mourtas, S., Lazar, A. N., Markoutsa, E., Duyckaerts, C., & Antimisiaris, S. G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.050 · Cited by 263 · cited 3×
“curcumin-conjugated nanoliposomes (Mourtas et al., 2014).”
BackgroundResultInfluentialClinical development of curcumin in neurodegenerative disease
Hu, S., Maiti, P., Ma, Q., Zuo, X., Jones, M. R., Cole, G. M., & Frautschy, S. A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1044981 · Cited by 179 · cited 1×
“Extensive lines of evidence indicate that Aβ oligomer production, oxidative markers, and neuroinflammation are attenuated by administration of curcumin (Hu et al., 2015; Nasir Abbas Bukhari and Jantan, 2015).”
BackgroundRay, B., Bisht, S., Maitra, A., Maitra, A., & Lahiri, D. K. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101374 · Cited by 177
Meng, F., Asghar, S., Gao, S., Su, Z., Song, J., Huo, M., Meng, W., Ping, Q., & Xiao, Y. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.06.025 · Cited by 176
Shi, X., Zheng, Z., Li, J., Xiao, Z., Qi, W., Zhang, A., Wu, Q., & Fang, Y. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.045 · Cited by 108 · cited 1×
“In vitro studies suggest that curcumin attenuates Aβ-induced inflammatory responses in microglia by suppressing the ERK1/2 and p38 signaling pathways (Shi et al., 2015).”
BackgroundKuo, Y.-C., & Lin, C.-C. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s79528 · Cited by 56
Cited by
Curcumin, the golden spice in treating cardiovascular diseases
Li, H., Sureda, A., Devkota, H. P., Pittalà, V., Barreca, D., Silva, A. S., Tewari, D., Xu, S., & Nabavi, S. M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.01.010 · Cited by 339
Abrahams, S., Haylett, W. L., Johnson, G., Carr, J. A., & Bardien, S. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.02.020 · Cited by 297
Fu, Y.-S., Chen, T.-H., Weng, L., Huang, L., Lai, D., & Weng, C.-F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111888 · Cited by 271
Curcumin, Gut Microbiota, and Neuroprotection
Di Meo, F., Margarucci, S., Galderisi, U., Crispi, S., & Peluso, G. (2019) · Nutrients · doi:10.3390/nu11102426 · Cited by 214
“In clinical trials, curcumin is effective on oxidative stress and inflammation at a dosage from 90 to 2000 mg/day [40–42], while in neurodegenerative diseases, prevention is evident at a dosage of 500–2000 mg [43].”
BackgroundIcariin alleviates osteoarthritis by inhibiting NLRP3-mediated pyroptosis
Zu, Y., Mu, Y., Li, Q., Zhang, S.-T., & Yan, H.-J. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1307-6 · Cited by 203
Metadata
- Authors
- Zhang, K., Chen, M., Du, Z.-Y., Zheng, X., Li, D.-L., & Zhou, R.-P.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2018
- Volume
- 13
- Issue
- 4
- Pages
- 742
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W2801804366
- Cited by
- 234
- References
- 18
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.